IZOMMED DSR Capsules – Esomeprazole 40 mg + Domperidone 30 mg
Composition: Each capsule contains Esomeprazole 40 mg and Domperidone 30mg in a sustained-release formulation, subject to confirmation from the approved product label.
Product Family: IZOMMED DSR belongs to the gastrointestinal medicine category, combining a proton pump inhibitor (esomeprazole) with a dopamine antagonist and prokinetic agent (domperidone).
Product Overview: IZOMMED DSR combines two active ingredients designed to address selected gastrointestinal symptoms. Esomeprazole reduces stomach acid production, while domperidone helps improve gastric motility and may relieve nausea and vomiting when appropriately prescribed.
Indications: Depending on the approved product labeling, this combination may be prescribed for selected patients with gastroesophageal reflux symptoms associated with delayed gastric emptying, nausea, or other relevant gastrointestinal symptoms. Treatment should be based on an appropriate clinical assessment.
Clinical Benefits: Esomeprazole helps reduce gastric acid and supports the management of acid-related conditions. Domperidone may help relieve nausea and improve upper gastrointestinal motility in selected patients. The combination may provide complementary symptom relief when both components are clinically appropriate.
Dosage and Administration: Use only as prescribed by a qualified healthcare professional and follow the approved product instructions. The exact formulation and release characteristics should be verified before determining the dose. Do not crush or chew a sustained-release capsule or its contents unless the product leaflet explicitly permits it.
Directions for Use: Take IZOMMED DSR according to the prescribed instructions. Inform the healthcare professional about existing medical conditions and all medicines being used before starting treatment.
Precautions: Domperidone can increase the risk of serious heart rhythm disturbances, including QT prolongation and potentially life-threatening arrhythmias. This risk may be higher in patients with heart disease, electrolyte abnormalities, significant liver impairment, or interacting medicines. Domperidone should be used at the lowest effective dose for the shortest duration permitted by local guidance. Esomeprazole may also interact with certain medicines, including clopidogrel.
Drug Interactions: Domperidone should not be combined with medicines that significantly prolong the QT interval or potent CYP3A4 inhibitors when contraindicated by the applicable product information. Esomeprazole may interact with clopidogrel and certain other medicines. A healthcare professional should review the patient's medication list before treatment.
Product Highlights: IZOMMED DSR combines acid suppression with a prokinetic agent in a single formulation for selected gastrointestinal conditions. Appropriate patient selection and careful review of cardiovascular risk are essential to safe use.
Product Summary: IZOMMED DSR combines esomeprazole 40 mg with domperidone 30 mg, reportedly in a sustained-release formulation. The exact strength, dosage form, approved indications, and release characteristics must be verified against the registered product label before publication.
Medical Notice: This description is intended for informational and professional website use. Domperidone-containing products have important cardiovascular safety restrictions. Confirm local registration and prescribing requirements before marketing or recommending this product.
Company: INTERMED